Temporal profiles of blood pressure, circulating nitric oxide, and adrenomedullin as predictors of clinical outcome in acute ischemic stroke patients

Molecular Medicine Reports

Volumn 13, Issue 5, 2016, Pages 3724-3734

  Serrano Ponz, Marta ^a   Rodrigo Gasqué, Carmen ^b   Siles, Eva ^c   Martínez Lara, Esther ^c   Ochoa Callejero, Laura ^d   Martínez, Alfredo ^d  

^a Servicio Neurologia   (Spain)

^b HOSPITAL SAN PEDRO   (Spain)

^c UNIVERSITY OF JAÉN   (Spain)

^d CENTER FOR BIOMEDICAL RESEARCH OF LA RIOJA CIBIR   (Spain)

Author keywords

Adrenomedullin; Blood pressure variability; Ischemic stroke; Nitric oxide; Temporal profiles

Indexed keywords

ADRENOMEDULLIN; NITRIC OXIDE;

AGED; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE VARIABILITY; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PROGNOSIS; PROSPECTIVE STUDY; RANKIN SCALE; SEX DIFFERENCE; STROKE PATIENT; SYSTOLIC BLOOD PRESSURE; ACUTE DISEASE; BLOOD; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DISEASE FREE SURVIVAL; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; SURVIVAL RATE; VERY ELDERLY;

ACUTE DISEASE; ADRENOMEDULLIN; AGED; AGED, 80 AND OVER; BLOOD PRESSURE; BRAIN ISCHEMIA; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NITRIC OXIDE; STROKE; SURVIVAL RATE;

EID: 84964720169     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2016.5001     Document Type: Article

References (59)

1. Albers GW, Caplan LR, Easton JD, Fayad PB, Mohr JP, Saver JL and Sherman DG; TIA Working Group: Transient ischemic attack-proposal for a new definition. N Engl J Med 347:1713-1716, 2002.
2. Albers GW: Acute cerebrovascular syndrome: Time for new terminology for acute brain ischemia. Nat Clin Pract Cardiovasc Med 3:521, 2006.
3. Mendis S, Davis S and Norrving B: Organizational update: The world health organization global status report on noncommunicable diseases 2014; one more landmark step in the combat against stroke and vascular disease. Stroke 46:e121-e122, 2015.
4. Sarikaya H, Ferro J and Arnold M: Stroke prevention-medical and lifestyle measures. Eur Neurol 73:150-157, 2015.
5. Jickling GC and Sharp FR: Biomarker panels in ischemic stroke. Stroke 46:915-920, 2015.
6. Wang Z, Lin Y, Liu Y, Chen Y, Wang B, Li C, Yan S, Wang Y and Zhao W: Serum uric acid levels and outcomes after acute ischemic stroke. Mol Neurobiol, 2015 (Epub ahead of print).
7. Rodrigo J, Fernández AP, Serrano J, Peinado MA and Martínez A: The role of free radicals in cerebral hypoxia and ischemia. Free Radic Biol Med 39:26-50, 2005.
8. Terpolilli NA, Moskowitz MA and Plesnila N: Nitric oxide: Considerations for the treatment of ischemic stroke. J Cereb Blood Flow Metab 32:1332-1346, 2012.
9. Garry PS, Ezra M, Rowland MJ, Westbrook J and Pattinson KT: The role of the nitric oxide pathway in brain injury and its treatment-from bench to bedside. Exp Neurol 263:235-243, 2015.
10. Ho JJ, Man HS and Marsden PA: Nitric oxide signaling in hypoxia. J Mol Med (Berl) 90:217-231, 2012.
11. Ito Y, Ohkubo T, Asano Y, Hattori K, Shimazu T, Yamazato M, Nagoya H, Kato Y and Araki N: Nitric oxide production during cerebral ischemia and reperfusion in eNOS- and nNOS-knockout mice. Curr Neurovasc Res 7:23-31, 2010.
12. Martínez-Murillo R, Fernández AP, Serrano J, Rodrigo J, Salas E, Mourelle M and Martínez A: The nitric oxide donor LA 419 decreases brain damage in a focal ischemia model. Neurosci Lett 415:149-153, 2007.
13. Willmot M, Gray L, Gibson C, Murphy S and Bath PM: A systematic review of nitric oxide donors and L-arginine in experimental stroke; effects on infarct size and cerebral blood flow. Nitric Oxide 12:141-149, 2005.
14. Paspalj D, Nikic P, Savic M, Djuric D, Simanic I, Zivkovic V, Jeremic N, Srejovic I and Jakovljevic V: Redox status in acute ischemic stroke: Correlation with clinical outcome. Mol Cell Biochem 406:75-81, 2015.
15. Serrano J, Uttenthal LO, Martínez A, Fernández AP, Martínez de Velasco J, Alonso D, Bentura ML, Santacana M, Gallardo JR, Martínez-Murillo R, et al: Distribution of adrenomedullin-like immunoreactivity in the rat central nervous system by light and electron microscopy. Brain Res 853:245-268, 2000.
16. López J and Martínez A: Cell and molecular biology of the multifunctional peptide, adrenomedullin. Int Rev Cytol 221:1-92, 2002.
17. Garayoa M, Martínez A, Lee S, Pío R, An WG, Neckers L, Trepel J, Montuenga LM, Ryan H, Johnson R, et al: Hypoxia-inducible factor-1 (HIF-1) up-regulates adrenomedullin expression in human tumor cell lines during oxygen deprivation: A possible promotion mechanism of carcinogenesis. Mol Endocrinol 14:848-862, 2000.
18. Serrano J, Alonso D, Encinas JM, Lopez JC, Fernandez AP, Castro-Blanco S, Fernández-Vizarra P, Richart A, Bentura ML, Santacana M, et al: Adrenomedullin expression is up-regulated by ischemia-reperfusion in the cerebral cortex of the adult rat. Neuroscience 109:717-731, 2002.
19. Serrano J, Fernández AP, Sánchez J, Rodrigo J and Martínez A: Adrenomedullin expression is up-regulated by acute hypobaric hypoxia in the cerebral cortex of the adult rat. Brain Pathol 18:434-442, 2008.
20. Somay G, Halac GU, Uslu E and Aydin S: Plasma adrenomedullin in acute ischemic stroke. Neurosciences (Riyadh) 12:351-353, 2007.
21. Hurtado O, Serrano J, Sobrado M, Fernández AP, Lizasoain I, Martínez-Murillo R, Moro MA and Martínez A: Lack of adrenomedullin, but not complement factor H, results in larger infarct size and more extensive brain damage in a focal ischemia model. Neuroscience 171:885-892, 2010.
22. Duangjit S, Muangpaisan W, Chotinaiwattarakul W and Dharmasaroja P: Functional recovery at 3 months in stroke patients not receiving thrombolytic therapy: The comparison between patients arriving earlier and later than 4.5 h. J Stroke Cerebrovasc Dis 23:91-98, 2014.
23. Berzina G, Sveen U, Paanalahti M and Sunnerhagen KS: Analysing the modified rankin scale using concepts of the international classification of functioning, disability and health. Eur J Phys Rehabil Med, 2015 (Epub ahead of print).
24. Blanco JR, Jarrin I, Martinez A, Siles E, Larrayoz IM, Cañuelo A, Gutierrez F, Gonzalez-Garcia J, Vidal F and Moreno S; CoRIS-Biobanco: Shorter telomere length predicts poorer immunological recovery in virologically suppressed HIV-1-infected patients treated with combined antiretroviral therapy. J Acquir Immune Defic Syndr 68:21-29, 2015.
25. Martínez A, Elsasser TH, Bhathena SJ, Pío R, Buchanan TA, Macri CJ and Cuttitta F: Is adrenomedullin a causal agent in some cases of type 2 diabetes? Peptides 20:1471-1478, 1999.
26. Geeganage C, Tracy M, England T, Sare G, Moulin T, Woimant F, Christensen H, De Deyn PP, Leys D, O'Neill D, et al: Relationship between baseline blood pressure parameters (including mean pressure, pulse pressure and variability), and early outcome after stroke: Data from the tinzaparin in acute ischaemic stroke trial (TAIST). Stroke 42:491-493, 2011.
27. Minnerup J, Wersching H, Unrath M and Berger K: Explaining the decrease of in-hospital mortality from ischemic stroke. PLoS One 10:e0131473, 2015.
28. Pikija S, Trkulja V, Malojcic B, Mutzenbach JS and Sellner J: A high burden of ischemic stroke in regions of Eastern/Central Europe is largely due to modifiable risk factors. Curr Neurovasc Res 12:341-352, 2015.
29. Morales Vidal SG and Ruland S: Platelet antiaggregants in stroke prevention. Neurol Clin 31:633-657, 2013.
30. Hiramoto JS, Katz R, Weisman S and Conte M: Gender-specific risk factors for peripheral artery disease in a voluntary screening population. J Am Heart Assoc 3:e000651, 2014.
31. Stroke Unit Trialists' Collaboration: Organised inpatient (stroke unit) care for stroke. Cochrane Database Syst Rev 9: CD000197, 2013.
32. Ishitsuka K, Kamouchi M, Hata J, Fukuda K, Matsuo R, Kuroda J, Ago T, Kuwashiro T, Sugimori H, Nakane H, et al: High blood pressure after acute ischemic stroke is associated with poor clinical outcomes: Fukuoka stroke registry. Hypertension 63:54-60, 2014.
33. Tziomalos K, Giampatzis V, Bouziana SD, Spanou M, Papadopoulou M, Kostaki S, Dourliou V, Papagianni M, Savopoulos C and Hatzitolios AI: Elevated diastolic but not systolic blood pressure increases mortality risk in hypertensive but not normotensive patients with acute ischemic stroke. Am J Hypertens 28:765-771, 2015.
34. Yong M, Diener HC, Kaste M and Mau J: Characteristics of blood pressure profiles as predictors of long-term outcome after acute ischemic stroke. Stroke 36:2619-2625, 2005.
35. Wohlfahrt P, Krajcoviechova A, Jozifova M, Mayer O, Vanek J, Filipovsky J and Cifkova R: Low blood pressure during the acute period of ischemic stroke is associated with decreased survival. J Hypertens 33:339-345, 2015.
36. Vemmos KN, Tsivgoulis G, Spengos K, Zakopoulos N, Synetos A, Manios E, Konstantopoulou P and Mavrikakis M: U-shaped relationship between mortality and admission blood pressure in patients with acute stroke. J Intern Med 255:257-265, 2004.
37. Bath PM, Martin RH, Palesch Y, Cotton D, Yusuf S, Sacco R, Diener HC, Toni D, Estol C and Roberts R; PRoFESS Study Group: Effect of telmisartan on functional outcome, recurrence and blood pressure in patients with acute mild ischemic stroke: A PRoFESS subgroup analysis. Stroke 40:3541-3546, 2009.
38. Potter J, Mistri A, Brodie F, Chernova J, Wilson E, Jagger C, James M, Ford G and Robinson T: Controlling hypertension and hypotension immediately post stroke (CHHIPS)-a randomised controlled trial. Health Technol Assess 13: iii, ix-xi, 2009.
39. Sandset EC, Bath PM, Boysen G, Jatuzis D, Körv J, Lüders S, Murray GD, Richter PS, Roine RO, Terént A, et al: The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): A randomised, placebo-controlled, double-blind trial. Lancet 377:741-750, 2011.
40. Sandset EC, Murray GD, Bath PM, Kjeldsen SE and Berge E; Scandinavian Candesartan Acute Stroke Trial (SCAST) Study Group: Relation between change in blood pressure in acute stroke and risk of early adverse events and poor outcome. Stroke 43:2108-2114, 2012.
41. Bath PM and Krishnan K: Interventions for deliberately altering blood pressure in acute stroke. Cochrane Database Syst Rev 10: CD000039, 2014.
42. Stead LG, Gilmore RM, Vedula KC, Weaver AL, Decker WW and Brown RD Jr: Impact of acute blood pressure variability on ischemic stroke outcome. Neurology 66:1878-1881, 2006.
43. Fukuda K, Kai H, Kamouchi M, Hata J, Ago T, Nakane H, Imaizumi T and Kitazono T; FSR Investigators; steering committee of the Fukuoka Stroke Registry included: Day-by-day blood pressure variability and functional outcome after acute ischemic stroke: Fukuoka stroke registry. Stroke 46:1832-1839, 2015.
44. Rashid PA, Whitehurst A, Lawson N and Bath PM: Plasma nitric oxide (nitrate/nitrite) levels in acute stroke and their relationship with severity and outcome. J Stroke Cerebrovasc Dis 12:82-87, 2003.
45. Abdullah A, Ssefer V, Ertugrul U, Osman E, Esref A, Ugur CM, Adalet A, Yavuz Y, Faysal E and Nebahat T: Evaluation of serum oxidant/antioxidant balance in patients with acute stroke. J Pak Med Assoc 63:590-593, 2013.
46. Cure MC, Tufekci A, Cure E, Kirbas S, Ogullar S, Kirbas A, Unal H, Yuce S and Cakmak S: Low-density lipoprotein subfraction, carotid artery intima-media thickness, nitric oxide and tumor necrosis factor alpha are associated with newly diagnosed ischemic stroke. Ann Indian Acad Neurol 16:498-503, 2013.
47. Gonullu H, Aslan M, Karadas S, Kati C, Duran L, Milanlioglu A, Aydin MN and Demir H: Serum prolidase enzyme activity and oxidative stress levels in patients with acute hemorrhagic stroke. Scand J Clin Lab Invest 74:199-205, 2014.
48. Molnar T, Pusch G, Papp V, Feher G, Szapary L, Biri B, Nagy L, Keki S and Illes Z: The L-arginine pathway in acute ischemic stroke and severe carotid stenosis: Temporal profiles and association with biomarkers and outcome. J Stroke Cerebrovasc Dis 23:2206-2214, 2014.
49. Salom MG, Arregui B, Carbonell LF, Ruiz F, González-Mora JL and Fenoy FJ: Renal ischemia induces an increase in nitric oxide levels from tissue stores. Am J Physiol Regul Integr Comp Physiol 289:R1459-R1466, 2005.
50. Cui X, Chopp M, Zacharek A, Zhang C, Roberts C and Chen J: Role of endothelial nitric oxide synthetase in arteriogenesis after stroke in mice. Neuroscience 159:744-750, 2009.
51. Khan M, Sekhon B, Giri S, Jatana M, Gilg AG, Ayasolla K, Elango C, Singh AK and Singh I: S-Nitrosoglutathione reduces inflammation and protects brain against focal cerebral ischemia in a rat model of experimental stroke. J Cereb Blood Flow Metab 25:177-192, 2005.
52. Zhang H, Tang B, Yin CG, Chen Y, Meng QL, Jiang L, Wang WP and Niu GZ: Plasma adrenomedullin levels are associated with long-term outcomes of acute ischemic stroke. Peptides 52:44-48, 2014.
53. Xia CF, Yin H, Borlongan CV, Chao J and Chao L: Postischemic infusion of adrenomedullin protects against ischemic stroke by inhibiting apoptosis and promoting angiogenesis. Exp Neurol 197:521-530, 2006.
54. Wang X, Yue TL, Barone FC, White RF, Clark RK, Willette RN, Sulpizio AC, Aiyar NV, Ruffolo RR Jr and Feuerstein GZ: Discovery of adrenomedullin in rat ischemic cortex and evidence for its role in exacerbating focal brain ischemic damage. Proc Natl Acad Sci USA 92:11480-11484, 1995.
55. Pedreño M, Morell M, Robledo G, Souza-Moreira L, Forte-Lago I, Caro M, O'Valle F, Ganea D and Gonzalez-Rey E: Adrenomedullin protects from experimental autoimmune encephalomyelitis at multiple levels. Brain Behav Immun 37:152-163, 2014.
56. Ma S, Zhao H, Ji X and Luo Y: Peripheral to central: Organ interactions in stroke pathophysiology. Exp Neurol 272:41-49, 2015.
57. Liu J, Yan J, Greer JM, Read SJ, Henderson RD, Rose SE, Coulthard A and McCombe PA: Correlation of adrenomedullin gene expression in peripheral blood leukocytes with severity of ischemic stroke. Int J Neurosci 124:271-280, 2014.
58. Malfitano AM, Marasco G, Proto MC, Laezza C, Gazzerro P and Bifulco M: Statins in neurological disorders: An overview and update. Pharmacol Res 88:74-83, 2014.
59. Yamamoto C, Fukuda N, Jumabay M, Saito K, Matsumoto T, Ueno T, Soma M, Matsumoto K and Shimosawa T: Protective effects of statin on cardiac fibrosis and apoptosis in adrenomedullin-knockout mice treated with angiotensin II and high salt loading. Hypertens Res 34:348-353, 2011.